STOK
Income statement / Annual
Last year (2023), Stoke Therapeutics, Inc.'s total revenue was $8.78 M,
a decrease of 29.22% from the previous year.
In 2023, Stoke Therapeutics, Inc.'s net income was -$104.70 M.
See Stoke Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
Operating Revenue |
$8.78 M |
$12.41 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Cost of Revenue |
$0.00
|
$3.54 M
|
$2.23 M
|
$1.93 M
|
$450,000.00
|
$214,000.00
|
$113,000.00
|
Gross Profit |
$8.78 M
|
$8.87 M
|
-$2.23 M
|
-$1.93 M
|
-$450,000.00
|
-$214,000.00
|
-$113,000.00
|
Gross Profit Ratio |
1
|
0.72
|
0
|
0
|
0
|
0
|
0
|
Research and Development Expenses |
$82.23 M
|
$77.84 M
|
$54.17 M
|
$32.20 M
|
$23.76 M
|
$8.37 M
|
$3.60 M
|
General & Administrative Expenses |
$41.32 M
|
$38.92 M
|
$31.90 M
|
$20.85 M
|
$11.91 M
|
$4.41 M
|
$1.96 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$41.32 M
|
$38.92 M
|
$31.90 M
|
$20.85 M
|
$11.91 M
|
$4.41 M
|
$1.96 M
|
Other Expenses |
$0.00
|
$167,000.00
|
$140,000.00
|
$57,000.00
|
$2,000.00
|
-$10,000.00
|
-$4,000.00
|
Operating Expenses |
$123.55 M
|
$116.76 M
|
$86.07 M
|
$53.04 M
|
$35.68 M
|
$12.78 M
|
$5.55 M
|
Cost And Expenses |
$123.55 M
|
$116.76 M
|
$86.07 M
|
$53.04 M
|
$35.68 M
|
$12.78 M
|
$5.55 M
|
Interest Income |
$0.00
|
$3.12 M
|
$120,000.00
|
$744,000.00
|
$3.35 M
|
$270,000.00
|
$0.00
|
Interest Expense |
$0.00
|
$3.12 M
|
$120,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Depreciation & Amortization |
$2.47 M
|
$3.54 M
|
$2.23 M
|
$1.93 M
|
$450,000.00
|
$214,000.00
|
$113,000.00
|
EBITDA |
-$112.30 M |
-$102.81 M |
-$83.58 M |
-$50.32 M |
-$35.23 M |
-$12.57 M |
-$5.44 M |
EBITDA Ratio |
-12.79
|
-8.41
|
0
|
0
|
0
|
0
|
0
|
Operating Income Ratio |
-13.07
|
-8.41
|
0
|
0
|
0
|
0
|
0
|
Total Other Income/Expenses Net |
$10.07 M
|
$3.29 M
|
$260,000.00
|
$801,000.00
|
$3.35 M
|
$260,000.00
|
-$4,000.00
|
Income Before Tax |
-$104.70 M
|
-$101.07 M
|
-$85.81 M
|
-$52.24 M
|
-$32.33 M
|
-$12.52 M
|
-$5.56 M
|
Income Before Tax Ratio |
-11.92
|
-8.15
|
0
|
0
|
0
|
0
|
0
|
Income Tax Expense |
$0.00
|
-$7.96 M
|
-$1.09 M
|
-$1.63 M
|
-$3.80 M
|
$260,000.00
|
$0.00
|
Net Income |
-$104.70 M
|
-$93.11 M
|
-$84.71 M
|
-$50.61 M
|
-$28.52 M
|
-$12.52 M
|
-$5.56 M
|
Net Income Ratio |
-11.92
|
-7.51
|
0
|
0
|
0
|
0
|
0
|
EPS |
-2.38 |
-2.39 |
-2.31 |
-1.51 |
-1.59 |
-0.53 |
-0.43 |
EPS Diluted |
-2.38 |
-2.39 |
-2.31 |
-1.51 |
-1.59 |
-0.53 |
-0.43 |
Weighted Average Shares Out |
$43.99 M
|
$38.90 M
|
$36.74 M
|
$33.49 M
|
$17.97 M
|
$23.51 M
|
$12.79 M
|
Weighted Average Shares Out Diluted |
$43.99 M
|
$38.90 M
|
$36.74 M
|
$33.49 M
|
$17.97 M
|
$23.51 M
|
$12.79 M
|
Link |
|
|
|
|
|
|
|